Evidence map›Paper›PMID 34613969›Full record

ArticlePloS one2021

Louisiana Medicaid access for treatment and care for hepatitis C virus (LA-MATCH) project: A cross-sectional study protocol.

Hasheemah Afaneh, Susanne Straif-Bourgeois, Evrim Oral, Ashley Wennerstrom, Olivia Sugarman, William T Robinson, Angel Whittington, Edward Trapido

Abstract read
In one paragraph

Article in PloS one, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Hasheemah AfanehDepartment of Epidemiology, New Orleans School of Public Health, Louisiana State University Health Sciences Center, New Orleans, Louisiana, United States of America.ORCID 0000-0003-1650-2286
Susanne Straif-BourgeoisDepartment of Epidemiology, New Orleans School of Public Health, Louisiana State University Health Sciences Center, New Orleans, Louisiana, United States of America.ORCID 0000-0002-7545-1610
Evrim OralDepartment of Biostatistics, New Orleans School of Public Health, Louisiana State University Health Sciences Center, New Orleans, Louisiana, United States of America.ORCID 0000-0003-2976-0778
Ashley WennerstromDepartment of Behavioral and Community Health Sciences and Center for Healthcare Value & Equity, New Orleans School of Public Health, LSU Health Sciences Center-New Orleans, Louisiana State University Health Sciences Center, New Orleans, Louisiana, United States of America.
Olivia SugarmanDepartment of Behavioral and Community Health Sciences and Center for Healthcare Value & Equity, New Orleans School of Public Health, LSU Health Sciences Center-New Orleans, Louisiana State University Health Sciences Center, New Orleans, Louisiana, United States of America.ORCID 0000-0001-5682-9625
William T RobinsonDepartment of Behavioral and Community Health Sciences and Center for Healthcare Value & Equity, New Orleans School of Public Health, LSU Health Sciences Center-New Orleans, Louisiana State University Health Sciences Center, New Orleans, Louisiana, United States of America.
Angel WhittingtonUniversity of Louisiana at Monroe, Medicaid, Monroe, Lousiana, United States of America.
Edward TrapidoDepartment of Epidemiology, New Orleans School of Public Health, Louisiana State University Health Sciences Center, New Orleans, Louisiana, United States of America.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionThis article presents the Louisiana Hepatitis C Elimination Program's evaluation protocol underway at the Louisiana State University Health Sciences Center-New Orleans. With the availability of direct-acting antiviral (DAA) agents, the elimination of Hepatitis C (HCV) has become a possibility. The HCV Elimination Program was initiated by the Louisiana Department of Health (LDH) Office of Public Health (OPH), LDH Bureau of Health Services Financing (Medicaid), and the Louisiana Department of Public Safety and Corrections (DPSC) to provide HCV treatment through an innovative pricing arrangement with Asegua Therapeutics, whereby a fixed cost is set for a supply of treatment over five years. MATERIALS AND

methodsA cross-sectional study design will be used. Data will be gathered from two sources: 1) an online survey administered via REDCap to a sample of Medicaid members who are receiving HCV treatment, and 2) a de-identified data set that includes both Medicaid claims data and OPH surveillance data procured via a Data Use Agreement between LSUHSC-NO and Louisiana Medicaid. DISCUSSION: The evaluation will contribute to an understanding of the scope and reach of this innovative treatment model, and as a result, an understanding of areas for improvement. Further, this evaluation may provide insight for other states considering similar contracting mechanisms and programs.

Indexed as

Antiviral AgentsCross-Sectional StudiesHealth Services AccessibilityHepacivirusHepatitis CHumansLouisianaMedicaidNew OrleansUnited StatesAntiviral Agents

Identifiers

PMID34613969
PMCPMC8494345

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.